Compare MC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | CRSP |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.0B |
| IPO Year | 2014 | 2016 |
| Metric | MC | CRSP |
|---|---|---|
| Price | $65.86 | $47.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $72.88 | $70.29 |
| AVG Volume (30 Days) | 891.6K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | N/A | ★ $289,590,000.00 |
| Revenue This Year | $18.28 | $807.72 |
| Revenue Next Year | $17.22 | $172.52 |
| P/E Ratio | $90.46 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $51.06 | $44.12 |
| 52 Week High | $78.22 | $78.48 |
| Indicator | MC | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 37.08 |
| Support Level | $61.71 | N/A |
| Resistance Level | $71.87 | $59.61 |
| Average True Range (ATR) | 2.61 | 2.98 |
| MACD | 0.02 | -1.07 |
| Stochastic Oscillator | 35.65 | 2.69 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.